Embryonic Stem Cells Definition
An embryonic stem cell is a cell derived from the early stages of an embryo which is capable of differentiating into any type of body cell. Embryonic stem cells are capable of differentiating into any cell type because in the embryo that is what they are used for.
As the embryo grows and divides, cells which are generalized must become more and more specific as they divide. This eventually creates the different organs, tissues, and systems of an organism. Embryonic stem cells are totipotent,meaning they can divide into any other cell type within an animal. This is a process known as cellular differentiation.
After the sperm reaches an egg (oocyte), fertilization occurs and the DNA from the two cells merge into a single nucleus, in a single cell. This is the zygote and is technically an embryonic stem cell because as it divides it will differentiate into all of the cells of the body.
This cell and the first few divisions of this cell have the ability to become any type of tissue. This means that they have the ability to become an entire organism. Identical twins, for example, develop from the same zygote which accidentally separates when it begins to divide.
In medicine and research, scientists use pluripotent embryonic stem cells. These cells do not have the ability to become an entire organism. Rather, they are directed by signals from the early embryo which tell them which cell type to differentiate into. Scientists prefer these cells for many reasons.
First, they can be stored and maintained more easily. Totipotent cells have a tendency to differentiate quickly, and immediately try to become an organism. Pluripotent cells are waiting for a signal to divide and can be maintained for longer periods. Further, because pluripotent cells are simply waiting for the proper signals to tell them which cell type to become, they can easily be integrated into medical applications in which new tissue must be grown.
The use of embryonic stem cells is a very new form of medicine. For decades, the cause of many degenerative diseases and physical injuries has been understood. Tissue damage is the root cause of many of these ailments, and scientists have long been searching for a method of growing tissues which do not easily repair themselves. Because an embryonic stem cell is pluripotent and can become almost any cell in the body, these cells have long been studied for their possible use in medicine.
Since the late 1950s scientists have been trying to test various methods of growing tissue with an embryonic stem cell. The first clinical trials were in the late 1960s, but not much progress has been made. President Bush put a moratorium on using Federal funds for stem cell research, which was finally lifted by the Obama Administration in 2009. European countries have also faced an uphill battle in funding stem cell research. However, with advances in the science came new discoveries which allowed for more ethical harvesting of an embryonic stem cell. The first treatments with medicinal stem cells were in 2010.
Medically, the embryonic stem cell is limited in its current uses, though many novel applications are in the works. Current treatments focus on the replacement of damaged tissue from injury or disease. Of these, the first treatment approved by the FDA to undergo trials was replacing damaged tissue in spinal injuries.
Because nerve cells rarely regenerate, an embryonic stem cell can be used to replace the damaged nerve and restore function. In someone with a spinal injury, this means being able to walk again. For a blind person, this might mean being able to see again. While the treatment is still new and success is limited, it has shown some positive results.
Still, other medical advances are made with the embryonic stem cell, although these dont come as direct medical treatments but rather as the knowledge that stem cells give us. As an embryonic stem cell differentiates into its target tissue, scientists can study the chemicals and methods it uses to do so. Scientists can also alter the genome of these cells, and study the effects different mutations have on a cells functioning.
Between these two paths of discovery, scientists have assembled much information about how and why cells differentiate and divide. Using these tools, scientists are closing in on methods which would allow them to turn regular cell back into a pluripotent stem cell. These are known asinduced pluripotent stem cells. They are not embryonic stem cells, because they are not derived from an embryo. This process could not only fix injuries and ailments but could potentially reverse aging and prevent death.
On a less dramatic and grand scale, these methods are also being used to cure common diseases, such as diabetes. By learning how embryonic stem cells become pancreas cells and secrete insulin, scientists are learning the methods of converting other tissues to insulin-secreting tissues. This could help cure diabetes, often caused by the destruction of insulin-producing cells. If these were replaced with stem cells, or other cells were induced to become pancreas cells, the disease could be cured.
Other diseases, like cystic fibrosis, fragile x syndrome, and other genetic disorders are studied in embryonic stem cells. Not only can many cells be created, but they can be differentiated into different cell types. In this way, a scientist can build a picture of the disease from snapshots of each cell type, and understand exactly how the disease is affecting a person.
While there was once a concern that embryonic stem cells were being harvested without consent from unknowing women, the vast majority are now ethically harvested an in vitro fertilization clinics. In these clinics, in order to get a successful pregnancy, many eggs must be fertilized. Only one is implanted, and with the womans consent, the rest can be used to harvest embryonic stem cells. To do this, scientists extract some embryonic stem cells from an embryo when it is only a small ball of cells. This can be seen in the image below.
A harvested embryonic stem cell is placed in a petri dish with nutrients and is allowed to divide. Without any signals from the embryo, the cells remain pluripotent. They continue dividing, fill one dish, and they are transferred to many more dishes and continue to grow. After 6 months of this, they are considered a successful pluripotent embryonic stem cell line. They can then be used to study disease, be used in treatments, or be manipulated genetically to provide models for how cells work.
To test that these cells are indeed pluripotent stem cells, they are injected into mice with depressed immune systems. The mice must have depressed immune systems, or their bodies would naturally reject the human tissue. Once implanted into the mouse, successful pluripotent cells will form a small tumor called a teratoma. This small tumor has different tissue types and proves that the cell line is still pluripotent and can differentiate into different cell types.
There are also other types of stem cells, not to be confused with an embryonic stem cell. Embryonic stem cells are derived from embryos. There are also adult stem cells, umbilical cord stem cells, and fetal stem cells. Not only are these stem cells sometimes more ethically challenging, they are only multipotent, meaning they can only become a small range of cell types.
One example is umbilical cord blood stem cells, which have been used in medical treatments to treat various blood diseases and suppressed immune systems. The stem cells in the blood of the umbilical cord can differentiate into almost any type of blood or immune cell, making them multipotent. However, this limits their use in other areas of medicine.
There are also adult stem cells, which survive in various organs throughout the body. These cells are also multipotent, and can only differentiate into the kinds of tissue in which they are found. A common use of adult stem cells is the bone marrow transplant. In this procedure, a healthy donor must have their marrow extracted from their bones. The marrow is a blood-like substance on the inside of large bones which creates blood cells and immune cells.
Cancer patients, having undergone radiation and chemotherapy, lose most of their immune cells and become immunocompromised. Often a bone marrow transplant is needed to replace these tissues. The new stem cells begin producing new immune cells, which help the patient recover and fight off infection and disease.
Go here to see the original:
Embryonic Stem Cell - Definition and Uses | Biology Dictionary
- RMS Sponsors the 5th Summit on Stem Cell Derived Islets - The Manila Times - October 30th, 2024
- Differentiation fate of a stem-like CD4 T cell controls immunity to cancer - Nature.com - October 30th, 2024
- Self-organization of stem cells into embryos: A window on early ... - October 24th, 2024
- Stemness and ROS: Redox Signaling and Regulation in Stem Cell Biology - Frontiers - October 24th, 2024
- Now its getting bloody in cardiac organoids - Nature.com - October 18th, 2024
- Embryonic stem cells - PMC - National Center for Biotechnology Information - October 15th, 2024
- They Were Made Without Eggs or Sperm. Are They Human? - The Atlantic - October 15th, 2024
- A novel investigation of NANOG and POU5F1 associations in the pluripotent characterization of ES-like and epiblast cells - Nature.com - October 15th, 2024
- Researchers uncover new mechanism of stem cell differentiation linked to cancer progression - News-Medical.Net - October 14th, 2024
- Stem Cells to Reverse Diabetes, the Spread of Marburg Virus and Map of a Fruit Fly Brain - Scientific American - October 14th, 2024
- Stem Cells Market Expectation Surges with Rising Demand and Changing Trends - openPR - October 11th, 2024
- How close are we to perfecting synthetic stem cells? - The Mancunion - October 10th, 2024
- Blood-generating heart-forming organoids recapitulate co-development of the human haematopoietic system and the embryonic heart - Nature.com - October 10th, 2024
- Revolutionary stem cell transplant successfully closes vision-threatening holes in the eye - Study Finds - October 4th, 2024
- Early human development and stem cell-based human embryo models - October 4th, 2024
- No partner, no problem: How people in the future might be able to have children with themselves - RNZ - October 4th, 2024
- Californias Billion-Dollar Stem Cell Initiatives End In Failure OpEd - Eurasia Review - October 4th, 2024
- The Future Of Stem Cell Therapy With Dr Adeel Khan - Style Magazines - October 4th, 2024
- New Study Mapping Stem Cells Reveals Molecular Choreography Behind ... - September 30th, 2024
- Stem Cell Research at Johns Hopkins Institute of Basic Biomedical ... - September 30th, 2024
- Zack Wang , PhD - Hopkins Medicine - September 30th, 2024
- Jennifer Hartt Elisseeff , PhD - Hopkins Medicine - September 30th, 2024
- Dr. Elias Zambidis, MD, PhD - Baltimore, MD - Pediatric Cellular ... - September 30th, 2024
- Alan David Friedman , MD - Hopkins Medicine - September 30th, 2024
- Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research - Nature.com - September 30th, 2024
- Human Embryonic Stem Cells Market Insights and Growth Trends: Leading Players and Future Projections to 2031 - WhaTech - September 26th, 2024
- Zac Efron says stem cell therapy helped him heal from The Iron Claw injuries - Daily Mail - September 25th, 2024
- The Role of Stem Cell Therapy in the Future of Personalized Medicine - HIT Consultant - September 25th, 2024
- Stem Cell Therapy Market to Exceed $831.9 Million by 2032 with 17.2% CAGR Growth - openPR - September 14th, 2024
- Brain Builders: How Stem Cell Research Is Rewriting the Genetic Code of Mental Health - SciTechDaily - September 14th, 2024
- Pausing biological clock could give boost to lab-produced blood stem cells - Phys.org - September 10th, 2024
- Alive and Kicking: Watch this space on controversy-free stem-cell ... - September 8th, 2024
- After 25 years of hype, embryonic stem cells still don't cure for ... - September 8th, 2024
- Human embryonic stem cells: origin, properties and applications - September 8th, 2024
- Livestock embryonic stem cells for reproductive biotechniques and ... - September 8th, 2024
- Marinexcell: Our Vision Is To Create a Sustainable and Reliable Source of Seafood Products - vegconomist - the vegan business magazine - September 6th, 2024
- How cells enter the germline at the right time and place during embryonic development - MRC Laboratory of Molecular Biology - September 6th, 2024
- Diabetes took over her life, until a stem cell therapy freed her - redlakenationnews.com - August 31st, 2024
- Diabetes took over her life, until a stem cell therapy freed her - The Washington Post - August 27th, 2024
- New way to extend shelf life of blood stem cells will improve gene therapy - University of Cambridge news - August 20th, 2024
- The anti-aging tech guy is now shooting $25,000 worth of stem cells into his knees. Here's why - Quartz - August 16th, 2024
- Substrates mimicking the blastocyst geometry revert pluripotent stem cell to naivety - Nature.com - August 12th, 2024
- Delivery of stem cell therapy for Parkinsons safe in primate trial - Parkinson's News Today - August 2nd, 2024
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - July 31st, 2024
- Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - July 31st, 2024
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - July 31st, 2024
- PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024 - July 31st, 2024
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 - July 31st, 2024
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 - July 31st, 2024
- Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency... - July 31st, 2024
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 - July 31st, 2024
- Appendix 4C – Q4 FY24 Quarterly Cash Flow Report - July 31st, 2024
- Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation - July 31st, 2024
- Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its... - July 31st, 2024
- Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference - July 31st, 2024
- Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors - July 31st, 2024
- electroCore to Announce Second Quarter June 30, 2024 Financial Results on Wednesday, August 7, 2024 - July 31st, 2024
- GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339 - July 31st, 2024
- New Study: These Bizarre Blood-Sucking Fish Have a Jaw-Dropping Evolutionary Origin - SciTechDaily - July 30th, 2024
- Surgeon Turns to Stem Cells to Help Treat Autism and Immune Disorders - The Well News - July 22nd, 2024
- Study identifies epigenetic 'switches' that regulate the developmental trajectories of single cells - Medical Xpress - July 22nd, 2024
- German Man Likely 'Cured' of HIV With Stem Cell Therapy - Times Now - July 22nd, 2024
- CervoMed to Participate in the Emerging Growth Conference - July 18th, 2024
- Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives - July 18th, 2024
- Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification - July 18th, 2024
- Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of... - July 18th, 2024
- Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of... - July 18th, 2024
- Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study - July 18th, 2024
- New Nature publication confirms CARBIOS’ leadership in enzymatic degradation of plastic - July 18th, 2024
- Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion - July 18th, 2024
- Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma - July 18th, 2024
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal - July 18th, 2024
- Scorpius Holdings Announces Reverse Stock Split - July 18th, 2024
- Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines - July 18th, 2024
- Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe... - July 18th, 2024
- Q2 2024 Revenue and Business Highlights, Guidance Upgrade - July 18th, 2024
- Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line... - July 18th, 2024
- Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance - July 18th, 2024
- BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of... - July 18th, 2024
- Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and... - July 18th, 2024
Recent Comments